Oncology dominates CRISPR landscape: GlobalData
Express Pharma
MARCH 6, 2024
Subsequently, it became the inaugural CRISPR-based drug for the hematological indications beta thalassemia and sickle cell disease (SCD). Despite this approval, the CRISPR landscape is dominated by oncology, which accounts for 30 per cent of all active CRISPR drugs.
111 
Let's personalize your content